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Objectives The aim of this study was to investigate the impact of bisphosphonates on the progression of aortic stenosis.
Background Valvular calcification is associated with the development and progression of aortic stenosis. Bisphosphonates
have been suggested to slow this progression.
Methods Female patients older than the age of 60 years with an aortic valve area (AVA) between 1.0 and 2.0 cm2 were
identified and studied retrospectively. Only those who had follow-up echocardiograms at least a year apart were
included. Primary outcomes were the change in AVA and valvular gradients over time. Mortality and freedom
from aortic valve replacement were also studied. A propensity-matching method was applied for the probability
of the use of bisphosphonates.
Results The study included 801 female patients (mean age, 76  7.6 years) with a mean follow-up of 5.1  2.4 years.
The mean duration of bisphosphonate use was 3.1  2.6 years. At the time of the initial echocardiogram, 323
patients (38%) were taking bisphosphonates. The mean ejection fraction at baseline was 56.7  9.6% with a
mean AVA of 1.32  0.25 cm2. Peak and mean gradients were 28.4  11 mm Hg and 15.6  6.8 mm Hg, re-
spectively. Propensity matching was successfully performed for 438 patients. On follow-up, there were no differ-
ences in the rate of change in AVA or peak and mean gradients when patients were stratified based on the use
of bisphosphonates. Bisphosphonates also had no impact on survival or freedom from aortic valve replacement.
Conclusions In this retrospective analysis of older female patients, bisphosphonates do not have a significant impact on the
hemodynamic or clinical progression of aortic stenosis. (J Am Coll Cardiol 2012;59:1452–9) © 2012 by the
American College of Cardiology Foundationi
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mAortic stenosis (AS) in the elderly is commonly associated
with leaflet calcification and thickening leading to progres-
sive obstruction of the aortic valve (1–6). As symptoms
ensue, the outcomes of these patients are poor, with a mean
survival of 2 years (7–10). The only intervention proven to
alter disease course is aortic valve replacement (AVR),
which normalizes the life expectancy to that of age- and
sex-matched controls (11). Because the disease becomes
more prevalent with the aging population, strategies to slow
down and reverse the progressive stenosis of the valve
become important, both from patient and population stand-
points. Such efforts should be based on a thorough study of
the histopathology and the mechanisms of progression of
AS. Retrospective studies of the use of statin therapy to slow
AS progression suggest a benefit in hyperlipidemic patients,
but prospective, randomized studies have not demonstrated
a significant favorable effect of statins on AS progression
(12–17).
Calcification has been shown to have a central role in the
progression of AS along with inflammation (1,3–5). Al-
though several trials have evaluated the role of statins in
altering the inflammatory process of the valve, calcification
has not been clearly targeted. Bisphosphonates, drugs that
are approved for use in patients with osteoporosis, have been
shown to inhibit vascular calcification (18–21). Further-
more, several small observational retrospective studies have
shown a possible link between the use of bisphosphonates
and slowing of AS progression (22–24). More recently, a
cross-sectional study of nitrogen-containing bisphospho-
nate therapy found an association with a lower prevalence of
cardiovascular calcification in women older than the age of
65 years (25). pIn our study, we sought to investigate the use of bispho-
sphonates in a large patient population to study the longi-
tudinal effects of these agents on the progression of AS.
Methods
Patient population. Women older than the age of 60 years
who were found to have mild to moderate AS (defined as an
aortic valve area [AVA] between 1.0 and 2.0 cm2) were
ncluded in the study. Those who did not have follow-up
chocardiograms at least a year apart were excluded. Study
ubjects were identified from the computerized echocardi-
graphy database at the Cleveland Clinic from January 2000
o January 2009. This study was performed after approval
rom the Institutional Review Board of the Cleveland Clinic
IRB #09-913).
Baseline characteristics including hypertension, hyperlip-
demia, chronic kidney disease, diabetes mellitus, and cor-
nary artery disease were obtained from electronic medical
ecords. The medications used by the patients including
isphosphonates, angiotensin-converting enzyme inhibi-
ors, angiotensin receptor blockers, beta-blockers, statins,
itamin D, and calcium supplements at the time of the
ndex echocardiogram were extracted from the electronic
edical records. Echocardiographic data included left ven-
ricular ejection fraction, AVA, aortic peak and mean
radients, and the presence and severity of mitral regurgi-
ation, tricuspid regurgitation, and right ventricular systolic
ressure. The effective AVA was obtained on 2-dimensional
chocardiography using the continuity equation. Peak and
ean gradients across the aortic valve were obtained usingulse and continuous wave Doppler evaluation of the aortic
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fraction was calculated using a
combination of the biplane Simp-
son method and 3-dimensional
measurements incorporating the
visual estimation as assessed by the
staff specialized in reading these
studies. Aortic valve calcification
was determined via a calcification score depending on severity
(0 to 3: none, mild, moderate, and severe, respectively) based
on the semiquantitative assessment by the staff interpreting the
imaging. Images and Doppler data were acquired by an
experienced sonographer and subsequently interpreted by staff
with expertise in echocardiographic imaging. Occurrence of
AVR was adjudicated using the databases kept at our center.
Mortality was assessed using Social Security Death Index.
Statistical analysis. The primary endpoint to be assessed
was the change in AVA and in peak and mean gradients
over time. Secondary endpoints evaluated were all-cause
mortality and freedom from AVR.
Continuous variables are expressed as mean  SD and
categorical variables as proportions. Continuous variables
were analyzed with a 2-sided Student t test, and categorical
variables were compared with the chi-square test. The
design of data collection ensured that the variables consid-
ered in the analysis were complete. Missing values were
imputed via mean value replacement. If a variable had
transformations, then that transformation was done on the
imputed value. If a variable was missing 50% of the time,
it was excluded from analysis.
After determining the use of bisphosphonates across the
cohort, patients were stratified based on the bisphosphonate
use. Two separate analyses were performed: 1) unadjusted
analysis of the entire cohort after stratification by bisphos-
phonate use, and 2) adjusted analysis after propensity
matching, in which patients not taking bisphosphonates
were matched to those taking bisphosphonates after solving
a saturated model for probability of bisphosphonate use.
AVA was analyzed longitudinally for change over time. A
nonlinear mixed model was used to resolve a number of time
phases on a cumulative odds domain to form a temporal
decomposition model and to estimate the shaping parame-
ters at each phase. Longitudinal cumulative logistic regres-
sion for repeated measurements (SAS PROC NLMIXED,
SAS Institute, Cary, North Carolina) was used to imple-
ment the temporal decomposition model. In this analysis,
all follow-up echocardiograms were factored into the anal-
ysis (ranging from 1 to 11 studies per patient). Initially, the
longitudinal model was used to find a trend in the data
during follow-up. Using this initially developed model, we
accounted for the nonindependence of the observations for
each person, creating a separate model for each patient. The
final model incorporated the best possible algorithm that
provided the best fit for all patients. The effect of bisphos-
phonates on the need for AVR and survival was studied
Abbreviations
and Acronyms
AS  aortic stenosis
AVA  aortic valve area
AVR  aortic valve
replacementwith the Kaplan-Meier nonparametric method. Survivalestimates were then estimated parametrically by a multi-
phase hazard model. The parametric model was used to
resolve a number of phases of instantaneous risk of death
(hazard function) and to estimate shaping parameters. To
determine the difference between group risk factors for
death, the indicator of bisphosphonate use was then added
to the multiphase hazard function domain. During all
computations of survival and freedom from AVR, the
follow-up period was divided into 2 phases (early and late)
to allow for the time-dependent effects of bisphosphonates.
Propensity matching. Using variables known at the time
of study entry and multivariable logistic regression, factors
associated with the use of bisphosphonates were deter-
mined. Subsequently, a propensity score was calculated for
each patient by solving the saturated model for the proba-
bility of bisphosphonate use. Using only the propensity
score, patients without a history of bisphosphonate use were
matched to patients with a history of bisphosphonate use
using a greedy matching strategy (26). With this strategy, a
bisphosphonate propensity score was considered matched to
the closest nonbisphosphonate propensity score within a
difference of 0.1. A nonbisphosphonate patient who was
matched was no longer eligible for consideration. This
algorithm was repeated until all patients taking bisphospho-
nates were matched or all propensity scores deviated 0.1
between the groups. Patients with a history of bisphospho-
nate use whose propensity scores deviated 0.1 from the
scores of those without a history of bisphosphonate use
were considered unmatched. All analyses were performed
using SAS statistical software versions 8.2 and 9.1 (SAS
Institute).
Results
Baseline variables and analysis of the unmatched cohort.
There were 801 female patients in the echocardiography
database who had an AVA between 1.0 and 2.0 cm2 and
older than 60 years of age who also had follow-up echocar-
diograms at least 1 year after the index study.
Of the total cohort of 801 patients, 313 (39%) were
taking bisphosphonates and 488 (61%) were not at the time
of the first echocardiogram. The mean duration of use of
bisphosphonates was calculated from the difference between
the first documentation of use and the last verified date of
use in the medical records, giving a mean duration of 3.1 
2.6 years. The severity of calcification based on mean
calcification score across both cohorts at the time of index
echocardiogram was similar (p  0.45). Analysis of the
baseline variables showed that patients who were taking
bisphosphonates were more likely to be older and have
hyperlipidemia and osteoporosis. Furthermore, if patients
were taking bisphosphonates, they were also more likely to
be taking vitamin D, calcium supplements, calcitonin, and
selective estrogen receptor modulators. The baseline echo-
cardiographic parameters were similar (Table 1).
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analyzed with a median follow-up period of 1.6 years (range,
0 to 9.2 years) after the qualifying echocardiogram (first
study after the index echocardiogram). The mean AVA at
the time of the index echocardiogram was 1.32  0.25 cm2.
indings were consistent with an overall rate of change that
as nonlinear in nature. There appeared to be a higher rate
f change for the first 3 years, which then stabilized at 0.05
m2 per year after 3 years.
When patients who were taking bisphosphonates and
hose who were not were compared, there was no significant
ifference in the rate of progression of the AVA when
hange was analyzed over time (p  0.87). The change in
eak and mean gradients was also similar across strata (p 
.75 and 0.43, respectively). Survival data were obtained
ith a mean follow-up of 3.1  2.3 years and a total of
,458 patient-years (with time 0 defined as the time of the
ualifying echocardiogram). Unadjusted analysis comparing
urvival between the bisphosphonate groups showed no
ignificant difference (p  0.53 and 0.70 for early and late
Baseline Characteristics ofthe Entire Cohor (N  801)*Table 1 B seline Characteristics ofthe Entire Cohort (N  801)*
No Bisphosphonates
(n  488)
Bisphosphonates
(n  313) p Value
Age, yrs 74.9 7.9 76.5 7.1 0.002
Comorbidities
Hypertension 221 (45) 159 (51) 0.1
Hyperlipidemia 155 (32) 130 (42) 0.005
CKD 14 (2.9) 10 (3.2) 0.8
Diabetes mellitus 94 (19) 52 (17) 0.3
CAD 107 (22) 64 (20) 0.6
Echo parameters
Ejection fraction 56.5 10 57 9 0.2
AV peak gradient 28.9 11.2 27.6 10.6 0.1
AV mean gradient 15.7 6.6 15.4 7.3 0.4
AVA 1.32 0.25 1.33 0.26 0.5
AVA index 0.77 0.17 0.88 0.47 0.2
AV calcification severity 0.45
Mild 47 (9.6) 23 (7.3)
Moderate 28 (5.7) 17 (5.4)
Severe 8 (1.6) 8 (2.6)
Medications
Vitamin D 199 (41) 225 (72) 0.0001
Calcium supplements 303 (62) 268 (86) 0.0001
Calcitonin 14 (2.9) 37 (12) 0.0001
SERM 28 (5.7) 30 (9.6) 0.04
ACE inhibitor 309 (63) 207 (66) 0.4
ARB 172 (35) 92 (29) 0.09
Beta-blocker 392 (80) 250 (80) 0.9
Statin 358 (73) 233 (74) 0.7
Values are mean  SD or n (%). *Demographic data, comorbidities, medications, and data for
rocedures performed at our institution were complete in all patients. Mortality data were
omplete for 792 patients (99%). AV peak and mean gradients were present for 799 patients
99%) and 797 patients (99%), respectively. AVA was available for all patients. Ejection fraction
ata were present for 787 patients (98%). Calcification data were present for 128 patients (16%).
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; AV  aortic valve;
AVA  aortic valve area; CAD  coronary artery disease; CKD  chronic kidney disease; Echo 
echocardiographic; SERM  selective estrogen receptor modulator.hases of follow-up, respectively). Occurrence of AVR waslso compared across study groups with a mean follow-up of
.5  1.9 years (time 0 defined as the time of the qualifying
chocardiogram). This analysis showed no difference across
isphosphonate groups with respect to freedom from AVR
p  0.33 and 0.55 for early and late phases, respectively).
nalysis after propensity matching according to the use
f bisphosphonates. From the cohort of 801 patients, a
otal of 438 patients were matched according to the use of
isphosphonates (219 patients in each group). After match-
ng, all measured baseline comorbid conditions, medica-
ions, and echocardiographic parameters were similar
Table 2). The severity of calcification at the time of the
ndex echocardiogram was similar in both groups (p 
.32). The C-statistic of the propensity-matching model
as 0.79.
In the matched cohort, the change in AVA over time was
nalyzed and showed no significant difference in the rate of
rogression of AVA across groups with a median follow-up
f 1.6 years (p  0.34) (Fig. 1A). This finding was also true
or the similarity in change in peak and mean gradients (p
.79 and 0.20, respectively) (Figs. 1B and 1C). Survival
nalysis did not show a significant difference between the
isphosphonate use groups for a mean follow-up of 3.1 
.3 years (p  0.94 and p  0.11 for early and late phases
uring follow-up, respectively) (Fig. 2A). Analysis evaluat-
Baseline Characteristics of theMatched ohort of Patients (n  438)Table 2 B seline Charact ristics of theMatched Cohort of Patients (n  438)
No Bisphosphonates
(n  219)
Bisphosphonates
(n  219) p Value
Age, yrs 75.9 7.7 75.8 7.2 0.8
Comorbidities
Hypertension 97 (44) 98 (45) 0.9
Hyperlipidemia 71 (32) 74 (34) 0.8
CKD 5 (2.3) 5 (2.3) 0.9
Diabetes mellitus 30 (14) 34 (16) 0.6
CAD 44 (20) 39 (18) 0.5
Echo parameters
Ejection fraction 57.1 9 56.6 9.1 0.9
AV peak gradient 28.1 11.9 27.8 10.6 0.7
AV mean gradient 15.3 6.9 15.5 7.7 0.6
AVA 1.33 0.25 1.33 0.26 0.9
AVA index 0.79 0.16 0.88 0.51 0.9
AV calcification severity 0.32
Mild 21 (9.5) 12 (5.5)
Moderate 14 (6.4) 8 (3.7)
Severe 5 (2.3) 7 (3.2)
Medications
Vitamin D 151 (69) 146 (67) 0.6
Calcium supplements 180 (82) 179 (82) 0.9
Calcitonin 14 (6.4) 13 (5.9) 0.8
SERM 19 (8.7) 19 (8.7) 0.9
ACE inhibitor 145 (66) 144 (66) 0.9
ARB 72 (33) 65 (30) 0.5
Beta-blocker 175 (80) 179 (82) 0.6
Statin 166 (76) 163 (74) 0.7Values are mean  SD or n (%).
Abbreviations as in Table 1.
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phosphonate groups for a mean follow-up of 1.5 1.9 years
p  0.26 and p  0.98 for early and late phases,
espectively) (Fig. 2B).
nalysis of patients who had AVR during follow-up. We
tudied the subset of patients who had AVR during
ollow-up to evaluate for the role of bisphosphonates in
isease progression in this patient subset (n  118). Of
hese patients, 77 were not taking bisphosphonates, with the
emaining 41 taking these agents. In the entire cohort of
18 patients, the rate of progression of AS as measured by
hange in AVA was high in the first year (0.17 cm2), which
then slowed in the subsequent years.
Analyzed with respect to the use of bisphosphonates
Figure 2 Effect of Bisphosphonate Use on Survival and
Freedom From AVR in the Propensity Matched Cohort
Analysis of the matched cohort of patients stratified by their bisphosphonate
use does not demonstrate any differences in survival (p  0.11) (A) or free-
dom from aortic valve replacement (AVR) (p  0.98) (B). (The number of bis-
phosphonate users at each time point is shown in the first row and nonusers
in the second row.) Echo  echocardiograms.Figure 1 Effect of Bisphosphonate Use
on Aortic Stenosis Progression
Analysis of the matched cohort of patients stratified by their bisphosphonate
use does not demonstrate any differences in change in aortic valve (AV) area
(p  0.34) (A), peak AV gradient (p  0.79) (B), or mean AV gradient (p 
0.20) (C), as demonstrated by Kaplan-Meier plots. (The number of patients
included at each time point is shown in the first row and number of echocar-
diograms [Echo] shown in the second row.)(median follow-up of 1.9 years), both treatment cohorts had
1457JACC Vol. 59, No. 16, 2012 Aksoy et al.
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time (p  0.07) (Fig. 3A) with their time course of
progression to AVR also being similar (p  0.66) (Fig. 3B).
Discussion
In this study of older women (older than 60 years of age)
with mild to moderate AS at baseline, we found that the use
of bisphosphonates did not affect the hemodynamic pro-
gression of valve stenosis. Furthermore, the use of bispho-
sphonates did not affect the survival or the rate of AVR
during follow-up. The study also illustrates that the rate of
progression of AS in this population is not linear but tends
to lessen over time.
Figure 3 Effect of Bisphosphonate Use on Progression of
Aortic Stenosis and Survival in Patients Undergoing AVR
Analysis of cohort of patients who underwent aortic valve replacement (AVR)
during follow-up does not show any differences in change in aortic valve area
(p  0.07) (A) or time course to AVR (p  0.66) (B). (For A, the number of
patients included at each time point is shown in the first row and the number
of echocardiograms [Echo] is shown in the second row. For B, the number of
bisphosphonate users at each time point is shown in the first row and nonus-
ers in the second row.)Our understanding of AS, a disease once thought to
result from a passive process of “wear-and-tear” of the valve,
has evolved in recent years (1,3–5,10,22). Now understood
to be the result of an active process of chronic inflammation
involving the renin-angiotensin system, lipid accumulation,
and calcium deposition, AS has been targeted by several
drugs in an effort to slow its progression. Statins have been
used to modify the chronic inflammation involved in the
disease progression with disappointing results in nonhyper-
lipidemic patients. Although retrospective data analyses had
suggested that the use of statins would be associated with
slowing of disease progression, randomized, controlled trials
have not demonstrated such clear benefit (12–17).
Angiotensin-converting enzyme inhibitors have also been
evaluated in retrospective studies with conflicting results
(27,28). As yet, no therapeutic option is available to slow the
rate of progression of stenosis in patients with mild to
moderate AS.
Calcification has been shown to be an integral part of
disease onset and progression in the histopathologic studies
of AS. Epidemiological studies have associated the in-
creased presence of calcium with adverse clinical outcomes
as well (29–31). As such, retarding, inhibiting, or reversing
the calcification of the valve might provide an avenue for
treatment of patients with mild to moderate AS. As an
active process, calcification of the aortic valve has been
associated with pathways that use osteopontin, bone mor-
phogenic proteins, and receptor activator of nuclear
factor-B ligand (32–34). Through complex interactions of
these molecules with those of lipid pathways and fibroblasts,
initial calcific nodules have been shown to form in regions of
lipid accumulation (5). Bisphosphonates are active in 2
pathways, which potentially could affect the pathophysiol-
ogy in AS. Nitrogen-containing bisphosphonates have been
shown to inhibit farnesyl-pyrophosphate synthase, an en-
zyme in the cascade in which ultimately statins exert their
effects (35). As a result, bisphosphonates have an effect
similar to that of the statins, by affecting lipid metabolism
and inflammation. Furthermore, bisphosphonates also pre-
vent bone resorption and slow the release of calcium
phosphate particles from the bone, which might play a role
in retarding calcium deposition in vascular and valvular
tissues (35,36). These effects of bisphosphonates have actu-
ally been evaluated in several small case series in which they
were shown to slow the progression of AS (22–24). How-
ever, these case series have included a total of 234 patients
with only 54 patients taking bisphosphonates, precluding
the generalizability of these results to a broader population.
Given the increasing prevalence of AS, medical therapies
that slow or reverse the progression of disease are urgently
needed from patient and population standpoints. In our
study, we evaluated the use of bisphosphonates in women
older than the age of 60 years with mild to moderate AS and
showed that bisphosphonates were not associated with any
beneficial effects in this patient population. Specifically, it
did not have any effect on the change in AVA over time,
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phonates did not delay surgery or slow the rate of narrowing
of the valve in patients who eventually underwent AVR.
This is in contrast to earlier case series, and although the
discrepancy can be partially explained by different patient
populations and the disease severity studied, the larger
sample size presented in this study is likely more reflective of
the role of bisphosphonates in the progression of AS.
This study is the largest retrospective analysis to date and
argues against the use of bisphosphonates in older women to
prevent the progression of AS. The potential reasons for the
negative results are multiple: Complex mechanisms are
involved in the regulation of calcium phosphate metabolism,
and bisphosphonates, effects on bone tissue may not be
replicated in the valve. Furthermore, the anti-inflammatory
effects of biphosphonates may not play a significant role in
the regulation of valvular inflammation. We also hypothe-
sized that the effects of potential positive effects of bispho-
sphonates on AS progression might be offset by the con-
comitant use of agents such as supplemental calcium and
vitamin D, which may accelerate the calcification process.
However, the propensity analysis (Table 2) allowed us
match for the use of these ancillary agents in both groups
and despite adequate matching of these agents, no effect of
bisphosphonates on progression was evident.
Many previous studies that have examined the progres-
sion of AS showed that the rate of change tends to be
relatively constant over time; however, these studies evalu-
ated the progression over a relatively short time frame and
used linear analysis, often using the annualized change in
valve area or pressure gradients as the mode of expression of
progression (37,38). Our study is novel in that it incorpo-
rated multiple echocardiograms in individual patients over a
longer period, suggesting that progression of AS, at least in
this population of women with mild to moderate AS, does
not have a true linear progression, but rather the progression
tends to slow after an early period of acceleration. Future
studies of longer term progression of AS should take into
account the likelihood of a nonlinear change in both valve
area and pressure gradients over time.
Study limitations. This study has several limitations. Its
etrospective nature exposes the data to unidentified sources
f bias, which might have led to findings of reduced efficacy
f bisphosphonates. We tried to circumvent this problem
ith propensity matching. However, we cannot account for
nmeasured variables by using this approach. We do not
ave data on patient compliance with taking bisphospho-
ates throughout the course of follow-up, nor did we match
or changes in therapy during follow-up. Furthermore,
isphosphonates are a large group of drugs, each with its
wn specific characteristics and affinities to distinct path-
ays in the calcification and inflammatory process. As such,
ategorizing all these drugs as 1 group might have prevented
s from identifying positive signals in the data. To further
lucidate the role of these drugs, research that evaluates the
ole of distinct bisphosphonates on valvular calcification isnecessary, together with prospective clinical studies to assess
for their efficacy in preventing the progression of AS.
Conclusions
In summary, in this largest study to date of the effect of
bisphosphonates on valvular disease progression, we show
that bisphosphonates do not have a significant impact on
the progression of AS. We believe that further studies are
necessary to better understand the mechanisms of calcifica-
tion and inflammation in AS to identify appropriate ther-
apeutic targets and drugs to modify the natural course of
disease.
Reprint requests and correspondence: Dr. Brian Griffin, Cleve-
land Clinic, 9500 Euclid Avenue/J1-5, Cleveland, Ohio 44195.
E-mail: griffib@ccf.org.
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